Asahi Kasei to Acquire Calliditas Therapeutics for $1.1 Billion in $1.05b Offer

May 28, 2024, 08:27 AM

Asahi Kasei has announced its acquisition of Swedish drugmaker Calliditas Therapeutics AB for approximately $1.1 billion. The deal will see Asahi Kasei paying SEK 416, or about USD $39.37 in cash per American Depositary Share (ADS). This acquisition marks the third successful exit for Sofinnova Partners, following the recent exits of Amolyt Pharma and LimFlow. Calliditas Therapeutics, known for its focus on rare diseases, will be integrated into Asahi Kasei's expanding pharmaceutical portfolio. The acquisition offer was valued at $1.05 billion.